Fatty Liver Disease

The most common form of liver disease around the world, Nonalcoholic Fatty Liver Disease (NAFLD) and its most aggressive form, Nonalcoholic Steatohepatitis (NASH) are not well-known among the general population, but their comorbid conditions like diabetes, obesity, and metabolic syndrome are.

35 %

of the US population has NAFLD

20 %

of the US population with NAFLD have NASH

Rimidi’s Approach to Fatty Liver Disease

The prevalence of obesity coupled with an aging population is making NAFLD and NASH the next silent epidemic in healthcare. Rimidi provides a comprehensive, progressive model of care that supports providers--from screening at-risk populations to risk stratification to get each patient to the appropriate level of care.

Identify At-Risk Patients

Whether a patient engages the health system through primary care, bariatrics, endocrinology or hepatology, Rimidi’s platform helps aggregate patient data directly through the EHR and identify the population at risk of NAFLD and NASH.

Guideline-Based Management

Once a patient is identified as at-risk, Rimidi provides a progressive care model, guiding physicians to the right level of intervention— whether that’s a specialist referral, bloodwork, or imaging.

Reduce your costs, and improve patient outcomes

Our goal is to help health systems achieve the quadruple aim of healthcare: better patient outcomes, lower costs, and improved patient and provider satisfaction. We'll show you how.